Latest SUPERSTRING CAPITAL MANAGEMENT LP Stock Portfolio
SUPERSTRING CAPITAL MANAGEMENT LP Performance:
2025 Q3: 21.17%YTD: 24.54%2024: -27.98%
Performance for 2025 Q3 is 21.17%, and YTD is 24.54%, and 2024 is -27.98%.
About SUPERSTRING CAPITAL MANAGEMENT LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, SUPERSTRING CAPITAL MANAGEMENT LP reported an equity portfolio of $101.5 Millions as of 30 Sep, 2025.
The top stock holdings of SUPERSTRING CAPITAL MANAGEMENT LP are ZLAB, CDTX, TERN. The fund has invested 6.7% of it's portfolio in ZAI LAB LTD and 6.5% of portfolio in CIDARA THERAPEUTICS INC .
The fund managers got completely rid off VERONA PHARMA PLC (VRNA), NEUROCRINE BIOSCIENCES INC (NBIX) and ULTRAGENYX PHARMACEUTICAL IN (RARE) stocks. They significantly reduced their stock positions in TRAVERE THERAPEUTICS INC (TVTX), ORIC PHARMACEUTICALS INC (ORIC) and COGENT BIOSCIENCES INC (COGT). SUPERSTRING CAPITAL MANAGEMENT LP opened new stock positions in CIDARA THERAPEUTICS INC (CDTX), IMMUNOVANT INC (IMVT) and SUMMIT THERAPEUTICS INC (SMMT). The fund showed a lot of confidence in some stocks as they added substantially to 89BIO INC (ETNB), TECTONIC THERAPEUTIC INC and ZAI LAB LTD (ZLAB).
The top stock holdings of SUPERSTRING CAPITAL MANAGEMENT LP are ZLAB, CDTX, TERN. The fund has invested 6.7% of it's portfolio in ZAI LAB LTD and 6.5% of portfolio in CIDARA THERAPEUTICS INC .
The fund managers got completely rid off VERONA PHARMA PLC (VRNA), NEUROCRINE BIOSCIENCES INC (NBIX) and ULTRAGENYX PHARMACEUTICAL IN (RARE) stocks. They significantly reduced their stock positions in TRAVERE THERAPEUTICS INC (TVTX), ORIC PHARMACEUTICALS INC (ORIC) and COGENT BIOSCIENCES INC (COGT). SUPERSTRING CAPITAL MANAGEMENT LP opened new stock positions in CIDARA THERAPEUTICS INC (CDTX), IMMUNOVANT INC (IMVT) and SUMMIT THERAPEUTICS INC (SMMT). The fund showed a lot of confidence in some stocks as they added substantially to 89BIO INC (ETNB), TECTONIC THERAPEUTIC INC and ZAI LAB LTD (ZLAB).
SUPERSTRING CAPITAL MANAGEMENT LP Annual Return Estimates Vs S&P 500
Our best estimate is that SUPERSTRING CAPITAL MANAGEMENT LP made a return of 21.17% in the last quarter. In trailing 12 months, it's portfolio return was 7.55%.
New Buys
| Ticker | $ Bought |
|---|---|
| cidara therapeutics inc | 6,556,020 |
| immunovant inc | 5,502,530 |
| summit therapeutics inc | 4,075,250 |
| iqvia hldgs inc | 3,630,510 |
| regeneron pharmaceuticals | 3,599,090 |
| bright minds biosciences inc | 3,272,610 |
| nektar therapeutics | 2,917,260 |
| avalo therapeutics inc | 2,390,500 |
New stocks bought by SUPERSTRING CAPITAL MANAGEMENT LP
Additions
| Ticker | % Inc. |
|---|---|
| 89bio inc | 81.12 |
| tectonic therapeutic inc | 50.88 |
| zai lab ltd | 48.73 |
| cabaletta bio inc | 45.6 |
| insmed inc | 35.79 |
| rapt therapeutics inc | 32.32 |
| savara inc | 17.38 |
Additions to existing portfolio by SUPERSTRING CAPITAL MANAGEMENT LP
Reductions
| Ticker | % Reduced |
|---|---|
| travere therapeutics inc | -80.6 |
| oric pharmaceuticals inc | -74.1 |
| cogent biosciences inc | -62.47 |
| terns pharmaceuticals inc | -38.63 |
| zenas biopharma inc | -13.39 |
| bridgebio pharma inc | -8.38 |
| jazz pharmaceuticals plc | -7.29 |
| bicara therapeutics inc | -7.27 |
SUPERSTRING CAPITAL MANAGEMENT LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| rocket pharmaceuticals inc | -525,309 |
| kyverna therapeutics inc | -437,604 |
| ultragenyx pharmaceutical in | -4,742,140 |
| ionis pharmaceuticals inc | -3,882,530 |
| ocular therapeutix inc | -825,734 |
| so young international inc | -226,102 |
| liquidia corporation | -885,545 |
| wave life sciences ltd | -456,573 |
SUPERSTRING CAPITAL MANAGEMENT LP got rid off the above stocks
Sector Distribution
SUPERSTRING CAPITAL MANAGEMENT LP has about 87.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 87.2 |
| Others | 12.8 |
Market Cap. Distribution
SUPERSTRING CAPITAL MANAGEMENT LP has about 16.6% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 39.2 |
| LARGE-CAP | 16.6 |
| MID-CAP | 16.6 |
| UNALLOCATED | 12.8 |
| MICRO-CAP | 10.9 |
| NANO-CAP | 3.9 |
Stocks belong to which Index?
About 59.3% of the stocks held by SUPERSTRING CAPITAL MANAGEMENT LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 52.2 |
| Others | 40.6 |
| S&P 500 | 7.1 |
SUPERSTRING CAPITAL MANAGEMENT LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of SUPERSTRING CAPITAL MANAGEMENT LP
SUPERSTRING CAPITAL MANAGEMENT LP has 35 stocks in it's portfolio. About 53.6% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. COGT was the most profitable stock for SUPERSTRING CAPITAL MANAGEMENT LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AVTX | avalo therapeutics inc | 2.36 | 188,080 | 2,390,500 | new | |||
| BBIO | bridgebio pharma inc | 4.54 | 88,658 | 4,604,900 | reduced | -8.38 | ||
| BMEA | biomea fusion inc | 0.50 | 250,000 | 505,000 | unchanged | 0.00 | ||
| CABA | cabaletta bio inc | 3.56 | 1,544,520 | 3,614,190 | added | 45.6 | ||
| CDTX | cidara therapeutics inc | 6.46 | 68,463 | 6,556,020 | new | |||
| COGT | cogent biosciences inc | 5.11 | 361,408 | 5,189,820 | reduced | -62.47 | ||
| CRBP | corbus pharmaceuticals hldgs | 0.72 | 57,644 | 729,197 | new | |||
| CYTK | cytokinetics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ETNB | 89bio inc | 5.57 | 384,652 | 5,654,380 | added | 81.12 | ||
| IMAB | i mab | 0.52 | 139,886 | 528,769 | new | |||
| IMVT | immunovant inc | 5.42 | 341,348 | 5,502,530 | new | |||
| INSM | insmed inc | 2.81 | 19,786 | 2,849,380 | added | 35.79 | ||
| IONS | ionis pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IPSC | century therapeutics inc | 0.23 | 462,963 | 230,556 | unchanged | 0.00 | ||
| IQV | iqvia hldgs inc | 3.58 | 19,114 | 3,630,510 | new | |||
| JAZZ | jazz pharmaceuticals plc | 5.31 | 40,893 | 5,389,700 | reduced | -7.29 | ||
| KROS | keros therapeutics inc | 1.48 | 95,083 | 1,504,210 | new | |||
| LQDA | liquidia corporation | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MLTX | moonlake immunotherapeutics | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NBIX | neurocrine biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||